Royal Bank Of Canada Beyond Spring Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.76 - $3.6 $1,436 - $2,937	816 Added 3400.0%	840 $2,000
Q1 2024 Nov 05, 2024	SELL	$0.85 - $3.63 $693 - $2,962	-816 Reduced 97.14%	24 $0
Q1 2024 May 15, 2024	SELL	$0.85 - $3.63 $124 - $533	-147 Reduced 85.96%	24 $0
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.12 $113 - $189	169 Added 8450.0%	171 $0
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.16 $324 - $501	-432 Reduced 99.54%	2 $0
Q2 2023 Aug 14, 2023	BUY	$0.89 - $1.39 $386 - $603	434 New	434 $0
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $1,554 - $3,660	-1,376 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $10,058 - $29,994	-5,987 Reduced 81.31%	1,376 $3,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $18,986 - $79,535	4,723 Added 178.9%	7,363 $33,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $10,241 - $34,628	1,106 Added 72.1%	2,640 $42,000
Q2 2021 Aug 16, 2021	BUY	$9.37 - $12.12 $14,373 - $18,592	1,534 New	1,534 $16,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.